Browsing Tag
Phase 2 clinical trials
2 posts
Lumosa Therapeutics reports Phase 2 functional gains for LT3001 in disabling acute ischemic stroke
Lumosa Therapeutics’ LT3001 Phase 2 stroke data show functional gains beyond standard windows. Find out what this means for Phase 3 and investors.
CVKD expands clinical pipeline with acquisition of VLX-1005, a Phase 2 12-LOX inhibitor for HIT patients
Discover how Cadrenal Therapeutics’ acquisition of VLX-1005 could reshape treatment options for heparin-induced thrombocytopenia and strengthen its anticoagulation pipeline.